GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (STU:ETF) » Definitions » Cyclically Adjusted PB Ratio

Elite Pharmaceuticals (STU:ETF) Cyclically Adjusted PB Ratio : (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Elite Pharmaceuticals Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Elite Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Elite Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Elite Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Elite Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Elite Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elite Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Elite Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Elite Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Elite Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.042/129.4194*129.4194
=0.042

Current CPI (Dec. 2023) = 129.4194.

Elite Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201403 -0.105 99.695 -0.136
201406 -0.109 100.560 -0.140
201409 -0.073 100.428 -0.094
201412 -0.041 99.070 -0.054
201503 -0.051 99.621 -0.066
201506 -0.021 100.684 -0.027
201509 -0.027 100.392 -0.035
201512 -0.081 99.792 -0.105
201603 -0.042 100.470 -0.054
201606 -0.038 101.688 -0.048
201609 0.022 101.861 0.028
201612 0.027 101.863 0.034
201703 0.026 102.862 0.033
201706 0.004 103.349 0.005
201709 0.007 104.136 0.009
201712 0.006 104.011 0.007
201803 0.005 105.290 0.006
201806 0.003 106.317 0.004
201809 0.002 106.507 0.002
201812 0.000 105.998 0.000
201903 -0.003 107.251 -0.004
201906 -0.002 108.070 -0.002
201909 -0.003 108.329 -0.004
201912 -0.005 108.420 -0.006
202003 -0.003 108.902 -0.004
202006 -0.002 108.767 -0.002
202009 0.012 109.815 0.014
202012 0.014 109.897 0.016
202103 0.013 111.754 0.015
202106 0.015 114.631 0.017
202109 0.017 115.734 0.019
202112 0.020 117.630 0.022
202203 0.023 121.301 0.025
202206 0.024 125.017 0.025
202209 0.027 125.227 0.028
202212 0.028 125.222 0.029
202303 0.027 127.348 0.027
202306 0.027 128.729 0.027
202309 0.042 129.860 0.042
202312 0.042 129.419 0.042

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Elite Pharmaceuticals  (STU:ETF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Elite Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Elite Pharmaceuticals (STU:ETF) Business Description

Traded in Other Exchanges
Address
165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Elite Pharmaceuticals (STU:ETF) Headlines

No Headlines